Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD22 (CD22 Molecule)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Labcorp® Plasma Complete™

Labcorp® Plasma Complete™

›

CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
CD22 positive	Lymphoma	CD22 positive	Lymphoma	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria inotuzumab ozogamicin Sensitive : C2
CD22 overexpression	Melanoma	CD22 overexpression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
CD22 overexpression	Acute Lymphocytic Leukemia	CD22 overexpression	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CD22 underexpression + BCL2 overexpression	Acute Lymphocytic Leukemia	CD22 underexpression + BCL2 overexpression	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3	inotuzumab ozogamicin Resistant: C3 – Early Trials inotuzumab ozogamicin Resistant : C3
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3
CD19 negative + CD20 negative + CD22 negative	B Acute Lymphoblastic Leukemia	CD19 negative + CD20 negative + CD22 negative	B Acute Lymphoblastic Leukemia	venetoclax + daratumumab Sensitive: C4 – Case Studies venetoclax + daratumumab Sensitive : C4	venetoclax + daratumumab Sensitive: C4 – Case Studies venetoclax + daratumumab Sensitive : C4
CD22 positive	T Cell Non-Hodgkin Lymphoma	CD22 positive	T Cell Non-Hodgkin Lymphoma	TRPH-222 Sensitive: D – Preclinical TRPH-222 Sensitive : D	TRPH-222 Sensitive: D – Preclinical TRPH-222 Sensitive : D